FDA panel votes to authorize Novavax COVID-19 vaccine

By Cassidy Morrison

Published June 7, 2022 7:41pm ET

Add Washington Examiner on Google

FDA panel votes to authorize Novavax COVID-19 vaccine — A vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London Wednesday, Oct. 7, 2020.

The Food and Drug Administration‘s panel of vaccine experts has voted overwhelmingly to authorize Novavax’s two-dose COVID-19 vaccine, paving the way for a new option that officials hope will attract unvaccinated people.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

COVID-19 FDA Public Health Vaccines Washington D.C.